SOUTH SAN FRANCISCO, Calif., Feb. 3, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Michael P. Miller to its Board of Directors. Mr. Miller has ...

Rigel Pharmaceuticals recently issued full-year 2026 guidance, projecting total revenue of about US$275 million to US$290 million, including US$255 million to US$265 million in net product sales and ...

SOUTH SAN FRANCISCO, Calif., Jan. 12, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today ...

Preliminary fourth quarter 2025 total revenue of approximately $69.8 million, including net product sales of $65.4 million and contract revenues of $4.4 million In the dose escalation phase of the ...

It has been seven years since my first Rigel Pharmaceuticals (RIGL) article, where I was bullish on TAVALISSE and the company's impressive pipeline. I was eyeing a potential buy early in 2019 as the ...

Don't miss 'The Curse of Rigel ' Expansion Launch Trailer for Wartales, an open-world turn-based strategy RPG developed by Shiro Games. Players will enforce the King's will to venture into the County ...

Rigel ( (RIGL)) has provided an announcement. On December 7, 2025, Rigel Pharmaceuticals announced updated data from its ongoing Phase 1b study of R289, an oral prodrug, in patients with relapsed or ...

Rigel Pharma is a profitable biotech with three FDA-approved drugs, experiencing accelerating revenue growth led by Tavalisse's strong performance. RIGL trades at a significant discount to biotech ...

Eli Lilly has pulled out of the central nervous system (CNS)-focused portion of a $960 million biobucks deal centered on Rigel Pharmaceuticals’ receptor-interacting serine/threonine-protein kinase 1 ...